US EditionTrump signs memo to crack down on direct-to-consumer pharma ads
The memo directs federal agencies to send thousands of enforcement letters to pharmaceutical companies and influencers for misleading ads, aiming to restore public trust and ensure full risk disclosure.
- President Donald Trump signed a memorandum to increase scrutiny on pharmaceutical ads, aiming for greater enforcement of regulations on drug advertising, as reported by administration officials.
- The U.S. Food and Drug Administration plans to eliminate a provision that allowed reduced disclosures in ads, aiming for more transparency.
- The administration will send over 100 cease-and-desist letters and thousands of warning letters to ensure compliance with existing regulations, according to a senior administration official.
- Trump's administration emphasized the need for accurate drug information to consumers, as ads have increasingly misled the public regarding side effects, a senior White House official stated.
108 Articles
108 Articles
Trump weighs crackdown on medicines from China - The Boston Globe
The Trump administration has been discussing severe restrictions on medicines from China that, if enacted, could upend the American pharmaceutical industry and availability of everything from generic drugs to cutting-edge treatments.
Trump Admin’s Drug Ad Crackdown Plan Faces Hurdles
Health Secretary Robert F. Kennedy Jr. and other administration officials are vowing a crackdown on deceptive drug ads, but the effort is likely to face multiple headwinds, including pushback from industry and layoffs among regulators tasked with leading the effort.
Associated Press News
Trump's plan for a drug advertising crackdown faces many hurdles
Health Secretary Robert F. Kennedy Jr. and other administration officials are vowing to crack down on deceptive drug ads, but they may encounter some major obstacles.
Trump Weighs Restrictions on Chinese Medicines
The Trump administration is considering sweeping restrictions on medicines originating from China, a move that could dramatically reshape the U.S. pharmaceutical industry and patient access to treatments. A draft executive order, obtained by The New York Times, would block American drugmakers from acquiring Chinese-invented experimental treatments and subject such deals to heightened national security review. The proposal also calls for incentiv…
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
